BioSpace News Archive

Puma Biotechnology, Inc., a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer patients at the EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium that is taking place in Barcelona, Spain.

Landmark Bio™ announced the opening of its state-of-the-art full-spectrum development and biomanufacturing facility in Watertown.

argenx SE announced its third quarter 2022 financial results and provided a business update and outlook for the remainder of the year.

FUJIFILM Diosynth Biotechnologies announced an agreement with argenx to manufacture efgartigimod, a monoclonal antibody fragment to target the neonatal Fc receptor, in patients with severe autoimmune disease.

Genentech, a member of the Roche Group, announced positive topline results from two global Phase III studies, BALATON and COMINO, evaluating the first and only bispecific antibody for the eye, Vabysmo®, in macular edema due to branch and central retinal vein occlusion.

Takeda announced financial results for the first half of fiscal year 2022, upgrading reported and core forecasts and free cash flow outlook for the fiscal year and reconfirming Management Guidance for core growth at constant exchange rate.

MorphoSys AG announced that its licensing partner, GSK plc, provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis.

Swedish Orphan Biovitrum AB announced its report for the third quarter of 2022.

Medidata, a Dassault Systèmes company, and Boehringer Ingelheim announced a five-year renewal of their collaboration in the wider area of electronic data capture.